(ANN ARBOR, Mich. – January 14, 2020) Swift Biosciences, Inc. ("Swift"), a leader in design and manufacturing of unique DNA and RNA library preparation and normalization kits for Next-Generation Sequencing (NGS), and MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, today announced a co-marketing agreement for Swift's DNA and RNA library preparation products in Europe and Asia Pacific markets. With this agreement, Swift and MGI will work to enable Swift's library preparation kits on MGI's D...

SAN FRANCISCO, CA,January 13, 2020 – MGI, one of the world’s leading manufacturers of DNA sequencing instruments, today launched its One Million Genomes Total Solution, a full-process software and hardware solution for one million genome projects. The integrated system will promote standardization and effectively solve the pain points in the industry and accelerate the arrival of the "genome for all" era, said Dr. Yongwei Zhang, BGI Group Vice President, speaking at the BUTTON Healthcare...

On January 9, 2020, Shenzhen Mammoth Public Welfare Foundation, Guangdong Xin'an Vocational and Technical College, and MGI held a "Mammoth Public Welfare Foundation-Genomics Teaching Lab" cooperation signing ceremony in Shenzhen National Gene Bank. The ceremony was attended by Jiang Weicheng, Executive Secretary of the Mammoth Public Welfare Foundation, Ye Weiqin, Dean of Guangdong Xin'an Vocational and Technical College, Wang Zhi, Associate Dean of Teaching, Liu Qiuhua, Deputy Director o...

MGI makes the following statement in response to Illumina's patent litigation in the UK and Sweden: We believe these claims have no merit and are typical Illumina tactics intended to maintain a monopolistic market position and prevent choice from being offered to customers. We intend to vigorously defend ourselves, as we have in other jurisdictions. The European Patent Office recently revoked three of Illumina’s DNA sequencing patents, and the Federal Trade Commission blocked Illumina’s prop...

MGI announced today that it has the market clearance for its G and T Series sequencers in Asia Pacific countries and Europe. Its DNBSEQ-T7, DNBSEQ-G400 and DNBSEQ-G50 sequencers are now cleared in European countries recognizing the CE-IVD mark and ready to position in clinical settings. The European IVD CE Mark approval opens up a wider global market with growing potential in clinical settings and enables MGI to serve more large-scale population sequencing projects, especially for DNBSEQ-...

From 2005, he began to learn classic experiments in plant research and genetics at the School of Life Sciences of Peking University. Today, he has led a team of more than 100 people to participate in world-class projects such as the "Earth Biological Genome Project" and "Thousand Plant Genome Projects" Liu Xin has quickly grown from a young boy to a leader in the field of genomics and has held positions such as executive vice president of Shenzhen BGI Research. Life science research need...